Wedbush Has Pessimistic View of Disc Medicine Q4 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Investment analysts at Wedbush reduced their Q4 2024 earnings per share estimates for shares of Disc Medicine in a report released on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.94) for the quarter, down from their prior estimate of ($0.89). Wedbush currently has a “Outperform” rating and a $83.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.15) per share. Wedbush also issued estimates for Disc Medicine’s Q1 2025 earnings at ($0.98) EPS, Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.10) EPS, FY2026 earnings at ($4.19) EPS and FY2027 earnings at $2.20 EPS.

Several other analysts also recently commented on the stock. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $66.00 to $110.00 in a research report on Monday, November 4th. HC Wainwright upped their price objective on Disc Medicine from $70.00 to $118.00 and gave the stock a “buy” rating in a research note on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a research note on Tuesday, October 15th. Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target for the company in a research note on Tuesday, November 5th. Finally, Jefferies Financial Group assumed coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price objective on the stock. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Disc Medicine presently has a consensus rating of “Buy” and a consensus price target of $85.80.

Disc Medicine Trading Down 2.0 %

Shares of IRON stock opened at $59.46 on Friday. The company has a 50 day simple moving average of $51.20 and a two-hundred day simple moving average of $44.97. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $77.60. The stock has a market cap of $1.77 billion, a P/E ratio of -14.94 and a beta of 0.60.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15.

Insider Activity at Disc Medicine

In related news, Director William Richard White sold 7,136 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders have sold 7,538 shares of company stock worth $437,875. Insiders own 4.24% of the company’s stock.

Institutional Trading of Disc Medicine

Several institutional investors and hedge funds have recently made changes to their positions in IRON. Amalgamated Bank increased its stake in Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after buying an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after acquiring an additional 337 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Disc Medicine during the third quarter valued at approximately $131,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Disc Medicine in the second quarter valued at approximately $129,000. Finally, Quantbot Technologies LP bought a new position in Disc Medicine in the third quarter worth approximately $146,000. 83.70% of the stock is currently owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.